Chronic Plaque-type Psoriasis

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Chronic Plaque-type Psoriasis trials may be worth asking about

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT07021495

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis…

Netherlands840 participantsStarted 2025-07-29Updated 2025-08-19

All recent trials (65 shown)

CompletedPhase 3

NCT03668613

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years,…

This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to…

United States, Belgium +7 more84 participantsStarted 2018-08-29Updated 2025-05-16

Treatment: secukinumab low dose, secukinumab high dose

CompletedPhase 3

NCT02660580

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaqu…

United States, Bulgaria +10 more443 participantsStarted 2016-02-16

Chronic Plaque-type Psoriasis

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

All recent trials (65 shown)

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years,…

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

All recent trials (65 shown)

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years,…

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Safety and Efficacy of Secukinumab in Mild Psoriasis

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe…

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Ps…

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chr…

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psori…

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderat…

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

A Study in Participants With Moderate to Severe Psoriasis